{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:43:37Z","timestamp":1791639817294,"version":"4.3.4"},"reference-count":55,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2026,4]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Paclitaxel\u2010induced peripheral neuropathy (PIPN) is a condition that persists chronically in more than 60% of affected individuals, and currently there are no proven PIPN prophylaxis. Pre\u2010clinical data suggest the angiotensin\u2010II\u2013receptor blocker losartan may attenuate neuro\u2010inflammation and nerve injury. This study was conducted to assess losartan's neuroprotective effect against PIPN in patients with breast cancer.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n In this single\u2010center, open\u2010label, randomized, controlled trial, women with early\u2010stage breast cancer scheduled for weekly paclitaxel (80\u2009mg\/mg\n 2<\/jats:sup>\n or 12 doses) were enrolled and randomized 1:1 to losartan 100\u2009mg once daily plus standard care or standard care alone. The primary end point was incidence of grade 2 or higher neuropathy, per National Cancer Institute Common Terminology Criteria of Adverse Events (NCI\u2010CTCAE v5.0). Secondary end points included time\u2010to\u2010neuropathy (in days), patient quality of life (QoL) assessed by Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group\u2010Neurotoxicity (FACT\/GOG\u2010NTX), pain intensity using visual\u2010analogue scale (VAS), serum nerve growth factor (NGF) levels, and safety.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Between December 2023 and December 2024, 89 Patients Were Randomized (Losartan,\n n<\/jats:italic>\n \u2009=\u200945; Control,\n n<\/jats:italic>\n \u2009=\u200944). Losartan Significantly Reduced Grade\u2009\u2265\u20092 Neuropathy Incidence (33.3% vs. 86.4%,\n p<\/jats:italic>\n \u2009<\u20090.001) and Delayed Its Onset (73.27 vs. 43.75\u2009Days; Hazards Ratio [\n HR<\/jats:styled-content>\n ]\u2009=\u20090.2, 95% Confidence Interval [\n CI<\/jats:styled-content>\n ]: 0.11\u20130.35) Compared With Standard Care Alone, Respectively. At 12\u2009Weeks, Patients Treated With Losartan Reported Superior\n QoL<\/jats:styled-content>\n (\n FACT<\/jats:styled-content>\n \/\n GOG<\/jats:styled-content>\n \u2010\n NTX<\/jats:styled-content>\n : 31.87\u2009\u00b1\u20096.43 vs. 15.45\u2009\u00b1\u200910.04;\n p<\/jats:italic>\n \u2009<\u20090.001) and Reduced Pain Scores (Median\n VAS<\/jats:styled-content>\n 3 vs. 8;\n p<\/jats:italic>\n \u2009<\u20090.001) Compared With Standard Care Alone, Respectively.\n NGF<\/jats:styled-content>\n Levels Were Comparable and Adverse Events Were Similar Between Groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Daily losartan reduced and delayed clinically significant paclitaxel\u2010induced neuropathy while improving patient\u2010reported outcomes, without additional toxicity. These findings support repurposing losartan as a low\u2010cost PIPN prophylactic and justify validation in larger, multicenter trials.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov<\/jats:ext-link>\n (\n NCT06135493<\/jats:ext-link>\n )\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/phar.70124","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:18:01Z","timestamp":1773058681000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Effect of Losartan in Preventing Paclitaxel\u2010Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study"],"prefix":"10.1002","volume":"46","author":[{"given":"Aalaa Mahmoud Ahmed Shawqi","family":"Mahmoud","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy Future University in Egypt Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Shash","sequence":"additional","affiliation":[{"name":"Breast Cancer Comprehensive Center of the National Cancer Institute, Cairo University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayam","family":"Ateyya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy Future University in Egypt Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida A.","family":"Okasha","sequence":"additional","affiliation":[{"name":"Breast Cancer Comprehensive Center of the National Cancer Institute, Cairo University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5663-4924","authenticated-orcid":false,"given":"Nouran Omar","family":"El Said","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy Future University in Egypt Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"crossref","unstructured":"L.WilkinsonandT.Gathani \u201cUnderstanding Breast Cancer as a Global Health Concern \u201d95(2022):1033.","DOI":"10.1259\/bjr.20211033"},{"issue":"2","key":"e_1_2_14_3_1","article-title":"Taxanes for Adjuvant Treatment of Early Breast Cancer","volume":"2019","author":"Willson M. L.","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15086"},{"issue":"10","key":"e_1_2_14_5_1","article-title":"Taxane\u2010Containing Regimens for Metastatic Breast Cancer","volume":"2015","author":"Ghersi D.","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0352-x"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.003"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13697"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43094\u2010024\u201000638\u2010w"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2024.117134"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxics9100229"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061451"},{"key":"e_1_2_14_14_1","doi-asserted-by":"crossref","unstructured":"J.Marques\u2010Lopes M.Pinto D.Pinho et\u00a0al. \u201cMicroinjection of Angiotensin Ii in the Caudal Ventrolateral Medulla Induces Hyperalgesia \u201d(2009.","DOI":"10.1016\/j.neuroscience.2008.11.044"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2014.11.018"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-019-1616-0"},{"key":"e_1_2_14_17_1","unstructured":"S. J.EnnaandD. B.Bylund \u201cLosartan. xPharm: The Comprehensive Pharmacology Reference [Internet] \u201d(2024) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526065\/."},{"issue":"2","key":"e_1_2_14_18_1","first-page":"120","article-title":"Losartan as a Reproposing Therapeutic Agent in Acute Respiratory Distress Syndrome: Modulating Inflammatory Responses and Cytokine Production","volume":"13","author":"Sripratak K.","year":"2024","journal-title":"International Journal of Molecular Medicine"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2023.09.001"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1515\/biol-2022-0583"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-024-01409-4"},{"issue":"1","key":"e_1_2_14_22_1","first-page":"1","article-title":"Angiotensin II Type 1 Receptor Antagonist Losartan Inhibits TNF\u2010\u03b1\u2010Induced Inflammation and Degeneration Processes in Human Nucleus Pulposus Cells","volume":"11","author":"Saravi B.","year":"2021","journal-title":"Applied Sciences (Switzerland)"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jot.2021.03.005"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-023-02937-0"},{"key":"e_1_2_14_25_1","article-title":"New Insights Into Repurposing of Renin\u2010Angiotensin System Inhibitors Against Alzheimer's Disease","volume":"15","author":"Mishra S.","year":"2024","journal-title":"Journal of Applied Pharmaceutical Science"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-024-00410-3"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084161"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15427"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.02.008"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08193-5"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102939"},{"key":"e_1_2_14_32_1","unstructured":"M. K.Bains S.Szombathy A.Bharmal andJ.Buston \u201cBC Cancer Clinical Pharmacy Guide \u201d(2024)."},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2005.05.002"},{"key":"e_1_2_14_34_1","unstructured":"CTCAE \u201cCommon Terminology Criteria of Adverse Events CTCAE Version 5 [Internet] \u201d(2017) https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html."},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01493-y"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2003.13603.x"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2004.06.024"},{"key":"e_1_2_14_38_1","unstructured":"S.De Santis A.Pace L.Bove et\u00a0al. \u201cPatients Treated With Antitumor Drugs Displaying Neurological Deficits Are Characterized by a Low Circulating Level of Nerve Growth Factor 1 \u201d6(2000):90 http:\/\/aacrjournals.org\/clincancerres\/article\u2010pdf\/6\/1\/90\/2073434\/df010000090.pdf."},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.18203\/2320-1770.ijrcog20162979"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(02)00048-9"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90126-4"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1181312"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1982_22"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2289-x"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b21-00852"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)02478-7"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464\u20105491.1995.tb00482.x"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100035\u20101550019"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00912-8"},{"key":"e_1_2_14_50_1","doi-asserted-by":"crossref","unstructured":"S.Elkholy E.Sweed A.Elfakharany A.Elsayed andM.ElBatsh \u201cP\u20101 Potential Neuroprotective Effects of Losartan and Donepezil on Oxaliplatin\u2010Induced Peripheral Neuropathy in Rats. Annals of Oncology [Internet] \u201d(2022) https:\/\/www.annalsofoncology.org\/action\/showFullText?pii=S0923753422007839.","DOI":"10.1016\/j.annonc.2022.04.093"},{"issue":"21","key":"e_1_2_14_51_1","first-page":"331","article-title":"Antinociceptive Effects of Angiotensin\u2010Converting Enzyme Inhibitors and an Angiotensin II Receptor Antagonist in Mice","volume":"59","author":"Takai S.","year":"1996","journal-title":"Life Science"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389450116666150825115658"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2016.1150179"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-51572-z"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1995.tb02050.x"},{"key":"e_1_2_14_56_1","doi-asserted-by":"crossref","unstructured":"A. I.Goldberg M. C.Dunlay andC. S.Sweet \u201cSafety and Tolerability of Losartan Potassium an Angiotensin II Receptor Antagonist Compared With Hydrochlorothiazide Atenolol Felodiprne ER. and Angiotensin\u2010Converting Enzyme Inhibitors for the Treatment of Systemic Hypertension \u201d(1995).","DOI":"10.1016\/S0002-9149(99)80413-5"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.70124","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T13:13:10Z","timestamp":1780146790000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/phar.70124"],"URL":"https:\/\/doi.org\/10.1002\/phar.70124","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2025-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70124"}}